GlassScriptPhysician profile
Stuart T Blevins
NPI 1013258201
$4,784.50
in general payments reported to CMS, 2019-2025
24 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,542 · 2022: $1,481 · 2023: $696 · 2024: $830 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $750.38 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $678.73 | 2021-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $598.88 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $529.25 | 2021-2025 | Spravato |
| Abbvie INC. | $491.70 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $468.66 | 2021-2022 | |
| Lundbeck LLC | $208.91 | 2021-2023 | Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $174.37 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $154.06 | 2021-2024 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.68 | 2022-2024 | Caplyta |
| Tris Pharma INC | $121.48 | 2023-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $108.31 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $70.01 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $62.74 | 2022-2024 | Qelbree |
| Neurocrine Biosciences, INC. | $48.66 | 2021-2024 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $39.92 | 2022-2024 | Perseris |
| Corium, LLC | $36.20 | 2022-2024 | Azstarys |
| Noven Pharmaceuticals, INC. | $20.61 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $17.03 | 2023 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $16.41 | 2021 | |
| Alfasigma USA, INC. | $15.77 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.14 | 2021 | |
| Eisai INC. | $13.85 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Blevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.